PTO/SB/21 (04-04) Approved for use through 07/31/2006. OMB 0651-0031

Under the Pa	IOBAITT A I		Application Number	10/618,2	.88	
IKAN	ISMITTAL		Filing Date	April 25,	2003	
	ORM		First Named Inventor	Thomas	E. Barta et al.	
(to be used for all con	rrespondence after initia	al filing)	Art Unit	1614		
			Examiner Name	Unknow	n	
Total Number of Pages	in This Submission		Attorney Docket Number	00988/1	/US (6794-000053/US	
		ENCLO	SURES (check all that apply)			
Fee Transmittal Fo	om	☐ Drawin	g(s)		Allowance Communication (TC)	
Fee Attached		Licensi	ing-related Papers		al Communication to Boa als and Interferences	
Amendment / Rep	ily	Petition	1		al Communication to TC al Notice, Brief, Reply Brie	
After Final			n to Convert to a ional Application	Propr	ietary Information	
Affidavits/decla	aration(s)		of Attorney, Revocation e of Correspondence Address	Status Letter		
Extension of Time	on of Time Request		Terminal Disclaimer		Other Enclosure(s) (please identify below):	
Express Abandonr	ment Request	Request for Refund  CD, Number of CD(s)		6	orm PTO-1449; References; eturn Receipt Postcard	
Information Disclos	sure Statement					
Certified Copy of F	Priority	F=***		. I		
Response to Missi Incomplete Applica						
Response to M Parts under 37 1.52 or 1.53						
	SIGNA	TURE OF	APPLICANT, ATTORNEY, (	OR AGENT		
Firm or Individual name	Harness, Dickey &	Pierce, P.L.	Attorney Name C. David M. Gryte		Reg. No. 11,809	
Signature			U		**	
Date	January 31, 2005					
	С	ERTIFICA	TE OF TRANSMISSION/MA	ILING	<u> </u>	
	t postage as first cla	ass mail in ar	simile transmitted to the USPTO n envelope addressed to: Mail Steep shown below			
Typed or printed name	<u> </u>		11	Express Mail Label No.	EV 327050975 US	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

January 31, 2005

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Signature



2-1-05

IFW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Thomas E. Barta, et al.

Serial No:

10/618,288

Filed: Title:

April 25, 2003
Piperidinyl- and Piperazinyl-Sulfonylmethyl Hydroxamic Acids and Their

Use as Protease Inhibitors

Confirmation No:

7868

Group Art Unit:

1614

Examiner:

Unknown

Attorney Ref:

00988/1/US

Pfizer Ref:

27378/USA

HDP Ref:

6794-000053/US

January 31, 2005

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing the Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this supplemental information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents are not admitting that such documents are necessarily relevant or prior art.

Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will

Supplemental Information Disclosure Statement Appl. No. 10/618,288 January 31, 2005



review for relevance every document listed on the attached form even if not initialed.

Some references cited in this information disclosure statement are U.S. patents or U.S. patent application publications. Copies of those references are therefore not being provided in accordance with 37 C.F.R. §1.98(a)(2)(i). Applicants, however, will provide copies of such references upon request from the Examiner.

Applicants request early and favorable consideration for this patent application.

\* \* \* \* \* \* \* \*

Applicants believe that they do not owe any fee in connection with this information disclosure statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

Respectfully submitted,

David M. Gryte, PTO Reg. No. 41,809

Harness, Dickey & Pierce 7700 Bonhomme, Suite 400 St. Louis, Missouri 63105

(314) 726-7500 (tel)

(314) 726-7501 (fax)

## CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on January 31, 2005 with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

DMG/PML enclosures

6	PEJO	6
	AN 3 1 2015	13 CF
BH	CA TRACE	I N

ORM HDP-1449 (Based on Form PTO-1449)

## PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.	SERIAL NO.
00988/1/US (Pfizer Ref. 27378/USA)	10/618,288
APPLICANT	
Thomas E. Barta, et al.	
FILING DATE	GROUP
April 25, 2003	1614

U.S. PATENT DO	CUMENTS					
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.		6,683,093	1/27/04	Barta, et al.	514/316	11/21/01
2.		6,689,794	2/10/04	Freskos, et al.	514/318	5/10/02
3. (notice of allowance enclosed)		6,800,646, including 11/21/03 notice of allowance	10/5/04	DeCrescenzo, et al.	514/316	9/30/02
4.		6,683,078	1/27/04	Barta, et al.	514/231.5	7/12/02
5. (pending claims and Office action enclosed)		Pending claims and 12/2/04 Office action from U.S. Appl. No. 10/887,450		Boehm et al.		7/8/04
6. (pending claims enclosed)		Pending claims from Appl. No. 10/700,202		McDonald et al.		11/3/03

FOREI	GN PATENT	DOCUMENTS					
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translat Yes	ion No
•							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)					
Ref. Desig.	Examiner's Initials				
7.		10/9/03 Search Report and 8/3/04 International Preliminary Examination Report from International Patent Application No. PCT/US03/13123			

Examiner:	Date Considered:	
Examine:	Date Considered.	